Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Daily Top 10 COVID-19 papers

DEU | ENG | ESP | FRA | ITA | POR | TUR | VNM


  Tuberculosis

  Free Subscription


Articles published in Clin Infect Dis

Retrieve available abstracts of 203 articles:
HTML format



Single Articles


    May 2020
  1. KABIR S, Rahman SMM, Ahmed S, Islam MS, et al
    Xpert Ultra assay on stool to diagnose pulmonary tuberculosis in children.
    Clin Infect Dis. 2020 May 18. pii: 5839814. doi: 10.1093.
    PubMed     Abstract available


  2. WALLES J, Tesfaye F, Jansson M, Balcha TT, et al
    Tuberculosis infection in women of reproductive age - a cross-sectional study at antenatal care clinics in an Ethiopian city.
    Clin Infect Dis. 2020 May 15. pii: 5837526. doi: 10.1093.
    PubMed     Abstract available


  3. SHIN SS, Modongo C, Zetola NM
    Twice-Daily vs. Once-Daily Dolutegravir in Patients With Human Immunodeficiency Virus-Tuberculosis Coinfection Receiving Rifampicin-Based Tuberculosis Therapy.
    Clin Infect Dis. 2020 May 14. pii: 5836979. doi: 10.1093.
    PubMed    


  4. DOOKIE N, Padayatchi N, Lessells RJ, Naicker CL, et al
    Individualised treatment of Multi-Drug Resistant Tuberculosis using Whole Genome Sequencing and Expanded Drug Susceptibility Testing.
    Clin Infect Dis. 2020 May 8. pii: 5834727. doi: 10.1093.
    PubMed     Abstract available


  5. PURYEAR SB, Fatch R, Beesiga B, Kekibiina A, et al
    Higher levels of alcohol use are associated with latent tuberculosis infection in adults living with HIV.
    Clin Infect Dis. 2020 May 6. pii: 5831355. doi: 10.1093.
    PubMed     Abstract available


    April 2020
  6. MARURI F, Guo Y, Blackman A, van der Heijden YF, et al
    Resistance-conferring mutations on whole-genome sequencing of fluoroquinolone-resistant and -susceptible M. tuberculosis isolates: a proposed threshold for identifying resistance.
    Clin Infect Dis. 2020 Apr 29. pii: 5827013. doi: 10.1093.
    PubMed     Abstract available


  7. BOARDMAN NJ, Moore T, Freiman J, Tagliaferri G, et al
    Pulmonary tuberculosis disease among immigrant detainees: rapid disease detection, high prevalence of asymptomatic disease and implications for tuberculosis prevention.
    Clin Infect Dis. 2020 Apr 16. pii: 5820624. doi: 10.1093.
    PubMed     Abstract available


  8. BOUTON TC, Jacobson KR
    Symptom screens are not sufficient: the fight against tuberculosis needs better weapons.
    Clin Infect Dis. 2020 Apr 16. pii: 5820627. doi: 10.1093.
    PubMed    


  9. ALVAREZ GG, Zwerling AA, Duncan C, Pease C, et al
    Molecular epidemiology of Mycobacterium tuberculosis to describe the transmission dynamics among Inuit residing in Iqaluit Nunavut using whole genome sequencing.
    Clin Infect Dis. 2020 Apr 13. pii: 5819740. doi: 10.1093.
    PubMed     Abstract available


  10. REUTER A, Furin J
    Treating drug-resistant tuberculosis infection: no more excuses.
    Clin Infect Dis. 2020 Apr 8. pii: 5817606. doi: 10.1093.
    PubMed    


    March 2020
  11. THOMAS BE, Kumar JV, Chiranjeevi M, Shah D, et al
    Evaluation of the accuracy of 99DOTS, a novel cellphone-based strategy for monitoring adherence to tuberculosis medications: Comparison of digital adherence data with urine isoniazid testing.
    Clin Infect Dis. 2020 Mar 28. pii: 5812993. doi: 10.1093.
    PubMed     Abstract available


  12. SCHMIT KM, Wortham JM, Ho CS, Powell KM, et al
    Analysis of severe adverse events reported among patients receiving isoniazid-rifapentine treatment for latent Mycobacterium tuberculosis infection - United States, 2012-2016.
    Clin Infect Dis. 2020 Mar 18. pii: 5809293. doi: 10.1093.
    PubMed     Abstract available


  13. SRINIVASAN V, Ha VTN, Vinh DN, Thai PVK, et al
    Sources of multi-drug resistance in patients with previous isoniazid resistant tuberculosis identified using whole genome sequencing: A longitudinal cohort study.
    Clin Infect Dis. 2020 Mar 13. pii: 5804256. doi: 10.1093.
    PubMed     Abstract available


  14. LOVEDAY M, Hughes J, Sunkari B, Master I, et al
    Maternal and infant outcomes among pregnant women treated for multidrug/rifampicin-resistant tuberculosis in South Africa.
    Clin Infect Dis. 2020 Mar 6. pii: 5788430. doi: 10.1093.
    PubMed     Abstract available


    February 2020
  15. WOODMAN M, Grandjean L
    Detecting Tuberculosis in Prisons: Switching Off the Disease at its Source.
    Clin Infect Dis. 2020 Feb 17. pii: 5736587. doi: 10.1093.
    PubMed    


  16. SANTOS ADS, Oliveira RD, Lemos EF, Lima F, et al
    Yield, Efficiency and Costs of Mass Screening Algorithms for Tuberculosis in Brazilian Prisons.
    Clin Infect Dis. 2020 Feb 17. pii: 5736588. doi: 10.1093.
    PubMed     Abstract available


  17. REICHLER MR, Khan A, Yuan Y, Chen B, et al
    Duration of Exposure Among Close Contacts of Patients With Infectious Tuberculosis and Risk of Latent Tuberculosis Infection.
    Clin Infect Dis. 2020 Feb 11. pii: 5733747. doi: 10.1093/cid/ciz1044.
    PubMed     Abstract available


    January 2020
  18. KORNFELD H, Sahukar SB, Procter-Gray E, Kumar NP, et al
    Impact of Diabetes and Low Body Mass Index on Tuberculosis Treatment Outcomes.
    Clin Infect Dis. 2020 Jan 19. pii: 5709634. doi: 10.1093.
    PubMed     Abstract available


  19. PARK JH, Choi EJ, Park HS, Choi SH, et al
    Treatment of latent tuberculosis infection based on the interferon-gamma releasing assay in allogeneic stem cell transplant recipients.
    Clin Infect Dis. 2020 Jan 13. pii: 5701499. doi: 10.1093.
    PubMed     Abstract available


  20. SOSSEN B, Broger T, Kerkhoff AD, Schutz C, et al
    'SILVAMP TB LAM' rapid urine tuberculosis test predicts mortality in hospitalized HIV patients in South Africa.
    Clin Infect Dis. 2020 Jan 9. pii: 5699650. doi: 10.1093.
    PubMed     Abstract available


  21. LI R, Nordio F, Huang CC, Contreras C, et al
    Two clinical prediction tools to improve tuberculosis contact investigation.
    Clin Infect Dis. 2020 Jan 6. pii: 5697300. doi: 10.1093/cid/ciz1221.
    PubMed     Abstract available


  22. RENS NE, Uyl-de Groot CA, Goldhaber-Fiebert JD, Croda J, et al
    Cost-Effectiveness of a Pharmacogenomic Test for Stratified Isoniazid Dosing in Treatment of Active Tuberculosis.
    Clin Infect Dis. 2020 Jan 6. pii: 5697286. doi: 10.1093/cid/ciz1212.
    PubMed     Abstract available


    December 2019
  23. BOGLIONE L, Lipani F, Lucchini AM, Salvador E, et al
    Antiviral therapy in patients with HBV treated for tuberculosis: a forgotten issue.
    Clin Infect Dis. 2019 Dec 17. pii: 5679635. doi: 10.1093/cid/ciz1199.
    PubMed    


  24. KENDALL EA, Malhotra S, Cook-Scalise S, Dowdy DW, et al
    Clinical impact of rapid drug susceptibility testing to accompany fluoroquinolone-containing universal tuberculosis regimens: a Markov model.
    Clin Infect Dis. 2019 Dec 9. pii: 5669959. doi: 10.1093/cid/ciz1179.
    PubMed     Abstract available


  25. NOGUERA-JULIAN A, Calzada-HernAndez J, Brinkmann F, Basu Roy R, et al
    Tuberculosis disease in children and adolescents on therapy with anti-tumor necrosis factor-alpha agents: a collaborative, multi-centre ptbnet study.
    Clin Infect Dis. 2019 Dec 4. pii: 5651260. doi: 10.1093/cid/ciz1138.
    PubMed     Abstract available


  26. NOLT D
    Granulomas and guidelines - the search for tuberculosis during TNF-alpha inhibition.
    Clin Infect Dis. 2019 Dec 4. pii: 5651255. doi: 10.1093/cid/ciz1139.
    PubMed    


    November 2019
  27. GUPTA-WRIGHT A, Fielding K, Wilson D, van Oosterhout JJ, et al
    Tuberculosis in hospitalised patients with HIV: clinical characteristics, mortality, and implications from the STAMP trial.
    Clin Infect Dis. 2019 Nov 29. pii: 5645290. doi: 10.1093/cid/ciz1133.
    PubMed     Abstract available


  28. WALSH KF, Koenig SP
    Missed Opportunities with Fatal Consequences: The Need for Earlier Initiation of Intensified Care for Patients at Highest Risk of Mortality from HIV-Associated Tuberculosis.
    Clin Infect Dis. 2019 Nov 29. pii: 5645295. doi: 10.1093/cid/ciz1134.
    PubMed    


  29. FLYNN AG, Aiona K, Haas MK, Reves R, et al
    Clinical Characteristics of Active Tuberculosis Diagnosed after Starting Treatment for Latent Tuberculosis Infection.
    Clin Infect Dis. 2019 Nov 27. pii: 5644105. doi: 10.1093/cid/ciz1157.
    PubMed     Abstract available


  30. RAVIMOHAN S, Maenetje P, Auld SC, Ncube I, et al
    A Common NLRC4 Gene Variant Associates With Inflammation and Pulmonary Function in Human Immunodeficiency Virus and Tuberculosis.
    Clin Infect Dis. 2019 Nov 22. pii: 5637499. doi: 10.1093.
    PubMed     Abstract available


  31. KEMPKER RR, Mikiashvili L, Zhao Y, Benkeser D, et al
    Clinical Outcomes among Patients with Drug-resistant Tuberculosis receiving Bedaquiline or Delamanid Containing Regimens.
    Clin Infect Dis. 2019 Nov 12. pii: 5622604. doi: 10.1093/cid/ciz1107.
    PubMed     Abstract available


  32. SEUNG KJ, Khan P, Franke MF, Ahmed S, et al
    Culture conversion at six months in patients receiving delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis.
    Clin Infect Dis. 2019 Nov 2. pii: 5611120. doi: 10.1093/cid/ciz1084.
    PubMed     Abstract available


    October 2019
  33. SVENSSON EM, Dian S, Te Brake L, Ganiem AR, et al
    Model-based meta-analysis of rifampicin exposure and mortality in Indonesian tuberculosis meningitis trials.
    Clin Infect Dis. 2019 Oct 30. pii: 5609415. doi: 10.1093/cid/ciz1071.
    PubMed     Abstract available


  34. SILVEIRA-MATTOS PS, Barreto-Duarte B, Vasconcelos B, Fukutani KF, et al
    Differential expression of activation markers by Mycobacterium tuberculosis-specific CD4+ T-cell distinguishes extrapulmonary from pulmonary tuberculosis and latent infection.
    Clin Infect Dis. 2019 Oct 30. pii: 5609412. doi: 10.1093/cid/ciz1070.
    PubMed     Abstract available


  35. KOENIG SP, Kim A, Shepherd BE, Cesar C, et al
    Increased Mortality after Tuberculosis Treatment Completion in Persons with HIV in Latin America.
    Clin Infect Dis. 2019 Oct 20. pii: 5601170. doi: 10.1093/cid/ciz1032.
    PubMed     Abstract available


  36. NAIDOO K, Hassan-Moosa R, Mlotshwa P, Yende-Zuma N, et al
    High Rates of Drug-induced Liver Injury in People Living With HIV Coinfected With Tuberculosis (TB) Irrespective of Antiretroviral Therapy Timing During Antituberculosis Treatment: Results From the Starting Antiretroviral Therapy at Three Points in TB
    Clin Infect Dis. 2019 Oct 17. pii: 5589114. doi: 10.1093.
    PubMed     Abstract available


  37. SINGH N
    Unique Rarity of Tuberculosis and Granulomatous Opportunistic Infections in Hematopoietic Cell Transplant Recipients.
    Clin Infect Dis. 2019 Oct 4. pii: 5581232. doi: 10.1093.
    PubMed    


    September 2019
  38. SHAH M, Paradis S, Betz J, Beylis N, et al
    Multicenter Study of the Accuracy of the BD MAX MDR-TB Assay for Detection of Mycobacterium tuberculosis Complex and Mutations Associated with Resistance to Rifampin and Isoniazid.
    Clin Infect Dis. 2019 Sep 27. pii: 5574845. doi: 10.1093.
    PubMed     Abstract available


  39. KUBJANE M, Berkowitz N, Goliath R, Levitt NS, et al
    Tuberculosis, HIV and the association with transient hyperglycaemia in peri-urban South Africa.
    Clin Infect Dis. 2019 Sep 26. pii: 5574636. doi: 10.1093.
    PubMed     Abstract available


  40. MASE S, Chorba T, Parks S, Belanger A, et al
    Bedaquiline for the Treatment of Multidrug-Resistant Tuberculosis in the United States.
    Clin Infect Dis. 2019 Sep 26. pii: 5574390. doi: 10.1093.
    PubMed     Abstract available


  41. SWIFT MD, Molella RG, Vaughn AIS, Breeher LE, et al
    Determinants of Latent Tuberculosis Treatment Acceptance and Completion in Healthcare Personnel.
    Clin Infect Dis. 2019 Sep 25. pii: 5573404. doi: 10.1093.
    PubMed     Abstract available


  42. AULD SC, Maenetje P, Ravimohan S, Weissman D, et al
    Declines in Lung Function After Antiretroviral Therapy Initiation in Adults With Human Immunodeficiency Virus and Tuberculosis: A Potential Manifestation of Respiratory Immune Reconstitution Inflammatory Syndrome.
    Clin Infect Dis. 2019 Sep 25. pii: 5573460. doi: 10.1093.
    PubMed     Abstract available


  43. DU Y, Qiu C, Chen X, Wang J, et al
    Treatment outcome of a shorter regimen containing clofazimine for multidrug-resistant tuberculosis: a randomized control trial in China.
    Clin Infect Dis. 2019 Sep 24. pii: 5573036. doi: 10.1093.
    PubMed     Abstract available


  44. WOLF A, Padayatchi N, Naidoo K, Master I, et al
    Spatial Temporal Clustering of Multi- and Extensively Drug Resistant Tuberculosis is Associated with HIV Status and Drug-susceptibility Pattern in KwaZulu-Natal, South Africa.
    Clin Infect Dis. 2019 Sep 20. pii: 5572101. doi: 10.1093.
    PubMed     Abstract available


    August 2019
  45. ZELNER J
    Is a more data-driven approach the future of Tuberculosis transmission modeling?
    Clin Infect Dis. 2019 Aug 17. pii: 5550891. doi: 10.1093.
    PubMed    


  46. WEINER J, Domaszewska T, Donkor S, Kaufmann SHE, et al
    Changes in transcript, metabolite and antibody reactivity during the early protective immune response in humans to Mycobacterium tuberculosis infection.
    Clin Infect Dis. 2019 Aug 15. pii: 5550193. doi: 10.1093.
    PubMed     Abstract available


    July 2019
  47. NELSON KN, Jenness SM, Mathema B, Lopman BA, et al
    Social mixing and clinical features linked with transmission in a network of extensively drug-resistant (XDR) tuberculosis cases in KwaZulu-Natal, South Africa.
    Clin Infect Dis. 2019 Jul 12. pii: 5531655. doi: 10.1093.
    PubMed     Abstract available


  48. ARONSON JR, Rezvani AR, Subramanian A
    Incidence of Active Tuberculosis Following Hematopoietic Cell Transplantation: A Small but Real Threat.
    Clin Infect Dis. 2019 Jul 11. pii: 5531496. doi: 10.1093.
    PubMed    


    June 2019
  49. XIN H, Zhang H, Yang S, Liu J, et al
    5-year follow-up of active tuberculosis development from latent infection in rural China.
    Clin Infect Dis. 2019 Jun 28. pii: 5525170. doi: 10.1093.
    PubMed     Abstract available


  50. DALE KD, Trauer JM, Dodd PJ, Houben RMGJ, et al
    Estimating long-term tuberculosis reactivation rates in Australian migrants.
    Clin Infect Dis. 2019 Jun 27. pii: 5524225. doi: 10.1093.
    PubMed     Abstract available


  51. SHARLING L, Marks SM, Goodman M, Chorba T, et al
    Rifampin-Resistant Tuberculosis In The United States, 1998-2014.
    Clin Infect Dis. 2019 Jun 22. pii: 5522413. doi: 10.1093.
    PubMed     Abstract available


  52. VERMA R, Swift BMC, Handley-Hartill W, Lee JK, et al
    A novel high sensitivity bacteriophage-based assay identifies low level M. tuberculosis bacteraemia in immunocompetent patients with active and incipient TB.
    Clin Infect Dis. 2019 Jun 22. pii: 5522421. doi: 10.1093.
    PubMed     Abstract available


  53. MALIK AA, Fuad J, Siddiqui S, Amanullah F, et al
    TB Preventive Therapy for individuals exposed to drug-resistant tuberculosis: feasibility and safety of a community-based delivery of fluoroquinolone-containing preventive regimen.
    Clin Infect Dis. 2019 Jun 12. pii: 5514486. doi: 10.1093.
    PubMed     Abstract available


  54. WALKER NF, Opondo C, Meintjes G, Jhilmeet N, et al
    Invariant Natural Killer T cell dynamics in HIV-associated tuberculosis.
    Clin Infect Dis. 2019 Jun 12. pii: 5514487. doi: 10.1093.
    PubMed     Abstract available


    May 2019
  55. REICHLER MR, Khan A, Sterling TR, Zhao H, et al
    Risk Factors for Tuberculosis and Effect of Preventive Therapy Among Close Contacts of Persons with Infectious Tuberculosis.
    Clin Infect Dis. 2019 May 24. pii: 5498700. doi: 10.1093.
    PubMed     Abstract available


  56. SALAZAR-AUSTIN N, Cohn S, Barnes GL, Tladi M, et al
    Improving TPT Uptake: A Cluster-Randomized Trial of Symptom-Based Versus Tuberculin Skin Test-Based Screening of Household Tuberculosis Contacts Less than 5 Years of Age.
    Clin Infect Dis. 2019 May 24. pii: 5498606. doi: 10.1093.
    PubMed     Abstract available


  57. YATES TA, Barr DA
    Tuberculosis and dysglycaemia.
    Clin Infect Dis. 2019 May 24. pii: 5498398. doi: 10.1093.
    PubMed    


  58. RAMACHANDRAN G, Chandrasekaran P, Gaikwad S, Hemanth Kumar AK, et al
    Sub-therapeutic rifampicin concentration is associated with unfavourable tuberculosis treatment outcomes.
    Clin Infect Dis. 2019 May 10. pii: 5487939. doi: 10.1093.
    PubMed     Abstract available


    April 2019
  59. GARDNER TOREN K, Spitters C, Pecha M, Bhattarai S, et al
    Tuberculosis in Older Adults: Seattle & King County, Washington.
    Clin Infect Dis. 2019 Apr 12. pii: 5448903. doi: 10.1093.
    PubMed     Abstract available


  60. HONG H, Dowdy DW, Dooley KE, Francis HW, et al
    Aminoglycoside-Induced Hearing Loss Among Patients Being Treated for Drug-Resistant Tuberculosis in South Africa: A Prediction Model.
    Clin Infect Dis. 2019 Apr 9. pii: 5432319. doi: 10.1093.
    PubMed     Abstract available


  61. UGARTE-GIL C, Alisjahbana B, Ronacher K, Riza AL, et al
    Diabetes mellitus among pulmonary tuberculosis patients from four TB-endemic countries: the TANDEM study.
    Clin Infect Dis. 2019 Apr 8. pii: 5431210. doi: 10.1093.
    PubMed     Abstract available


  62. TSANG CA, Shah N, Armstrong LR, Marks SM, et al
    Eligibility for a Shorter Treatment Regimen for Multidrug-resistant Tuberculosis in the United States, 2011-2016.
    Clin Infect Dis. 2019 Apr 4. pii: 5427063. doi: 10.1093.
    PubMed     Abstract available


    March 2019
  63. SURYAVANSHI N, Murrill M, Gupta A, Hughes M, et al
    Willingness to Take Multidrug-Resistant Tuberculosis (MDR-TB) Preventive Therapy among Adult and Adolescent Household Contacts of MDR-TB Index Cases: An International Multi-Site Cross-Sectional Study.
    Clin Infect Dis. 2019 Mar 28. pii: 5421246. doi: 10.1093.
    PubMed     Abstract available


  64. ROE J, Venturini C, Gupta RK, Gurry C, et al
    Blood transcriptomic stratification of short-term risk in contacts of tuberculosis.
    Clin Infect Dis. 2019 Mar 28. pii: 5421263. doi: 10.1093.
    PubMed     Abstract available


  65. DOOLEY KE, Kaplan R, Mwelase N, Grinsztejn B, et al
    Dolutegravir-Based Antiretroviral Therapy for Patients Co-Infected with Tuberculosis and Hiv: A Multicenter, Noncomparative, Open-Label, Randomized Trial.
    Clin Infect Dis. 2019 Mar 28. pii: 5421214. doi: 10.1093.
    PubMed     Abstract available


  66. GUPTA A, Swindells S, Kim S, Hughes MD, et al
    Feasibility of Identifying Household Contacts of Rifampin- and Multidrug-Resistant Tuberculosis Cases at High Risk of Progression to Tuberculosis Disease.
    Clin Infect Dis. 2019 Mar 28. pii: 5426963. doi: 10.1093.
    PubMed     Abstract available


  67. MAARTENS G, Meintjes G
    Managing HIV-associated tuberculosis in the dolutegravir era.
    Clin Infect Dis. 2019 Mar 25. pii: 5419061. doi: 10.1093.
    PubMed    


  68. LUI GCY, Wong NS, Wong RYK, Tse YK, et al
    Antiviral therapy for hepatitis B prevents liver injury in patients with tuberculosis and hepatitis B co-infection.
    Clin Infect Dis. 2019 Mar 22. pii: 5421304. doi: 10.1093.
    PubMed     Abstract available


  69. TORNHEIM JA, Starks AM, Rodwell TC, Gardy JL, et al
    Building the framework for standardized clinical laboratory reporting of next generation sequencing data for resistance-associated mutations in Mycobacterium tuberculosis complex.
    Clin Infect Dis. 2019 Mar 18. pii: 5382557. doi: 10.1093.
    PubMed     Abstract available


  70. RONALD LA, Campbell JR, Rose C, Balshaw R, et al
    Estimated impact of World Health Organization latent tuberculosis screening guidelines in a low TB incidence region: retrospective cohort study.
    Clin Infect Dis. 2019 Mar 11. pii: 5374592. doi: 10.1093.
    PubMed     Abstract available


  71. KATRAK S, Barry P
    Preventing tuberculosis disease - making a case for enhanced TB screening in people immigrating to low-incidence countries.
    Clin Infect Dis. 2019 Mar 11. pii: 5373169. doi: 10.1093.
    PubMed    


  72. ALFFENAAR JC, Heysell SK, Mpagama SG
    Therapeutic Drug Monitoring: The Need for Practical Guidance.
    Clin Infect Dis. 2019;68:1065-1066.
    PubMed    


    February 2019
  73. PERUMAL R, Padayatchi N, Yende-Zuma N, Naidoo A, et al
    A moxifloxacin-based regimen for the treatment of recurrent drug-sensitive pulmonary tuberculosis: An open-label randomised controlled trial.
    Clin Infect Dis. 2019 Feb 27. pii: 5365529. doi: 10.1093.
    PubMed     Abstract available


  74. BULABULA ANH, Nelson JA, Musafiri EM, Machekano R, et al
    Prevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF-identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012-2017: A Retrospective Province-Wide Cohort Study.
    Clin Infect Dis. 2019 Feb 13. pii: 5316466. doi: 10.1093/cid/ciy1105.
    PubMed     Abstract available


  75. POLSFUSS S, Hofmann-Thiel S, Merker M, Krieger D, et al
    Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment.
    Clin Infect Dis. 2019 Feb 2. pii: 5305974. doi: 10.1093.
    PubMed     Abstract available


    January 2019
  76. WALSH KF, Vilbrun SC, Souroutzidis A, Delva S, et al
    Improved Outcomes with High-Dose Isoniazid in Multidrug-Resistant Tuberculosis Treatment in Haiti.
    Clin Infect Dis. 2019 Jan 29. pii: 5304006. doi: 10.1093.
    PubMed     Abstract available


  77. BORAND L, de Lauzanne A, Nguyen NL, Cheng S, et al
    Isolation of Nontuberculous Mycobacteria in Southeast Asian and African Human Immunodeficiency Virus-infected Children With Suspected Tuberculosis.
    Clin Infect Dis. 2019 Jan 28. pii: 5303788. doi: 10.1093.
    PubMed     Abstract available


  78. CHENG MP, Kusztos AE, Bold TD, Ho VT, et al
    Risk of Latent Tuberculosis Reactivation after Hematopoietic-Cell Transplantation.
    Clin Infect Dis. 2019 Jan 28. pii: 5303791. doi: 10.1093.
    PubMed     Abstract available


    November 2018
  79. BOLHUIS MS, Akkerman OW, Sturkenboom MGG, Ghimire S, et al
    Linezolid-based Regimens for Multidrug-resistant Tuberculosis (TB): A Systematic Review to Establish or Revise the Current Recommended Dose for TB Treatment.
    Clin Infect Dis. 2018;67.
    PubMed     Abstract available


  80. STURKENBOOM MGG, Simbar N, Akkerman OW, Ghimire S, et al
    Amikacin Dosing for MDR Tuberculosis: A Systematic Review to Establish or Revise the Current Recommended Dose for Tuberculosis Treatment.
    Clin Infect Dis. 2018;67.
    PubMed     Abstract available


  81. SRIVASTAVA S, Deshpande D, Magombedze G, Gumbo T, et al
    Efficacy Versus Hepatotoxicity of High-dose Rifampin, Pyrazinamide, and Moxifloxacin to Shorten Tuberculosis Therapy Duration: There Is Still Fight in the Old Warriors Yet!
    Clin Infect Dis. 2018;67.
    PubMed     Abstract available


  82. MAGOMBEDZE G, Pasipanodya JG, Srivastava S, Deshpande D, et al
    Transformation Morphisms and Time-to-Extinction Analysis That Map Therapy Duration From Preclinical Models to Patients With Tuberculosis: Translating From Apples to Oranges.
    Clin Infect Dis. 2018;67.
    PubMed     Abstract available


  83. SRIVASTAVA S, Deshpande D, Nuermberger E, Lee PS, et al
    The Sterilizing Effect of Intermittent Tedizolid for Pulmonary Tuberculosis.
    Clin Infect Dis. 2018;67.
    PubMed     Abstract available


  84. FALZON D, Jaramillo E, Gilpin C, Weyer K, et al
    The Role of Novel Approaches and New Findings in the Pharmacology of Tuberculosis Medicines in Improving Treatment Outcomes.
    Clin Infect Dis. 2018;67.
    PubMed    


  85. DESHPANDE D, Pasipanodya JG, Mpagama SG, Bendet P, et al
    Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis.
    Clin Infect Dis. 2018;67.
    PubMed     Abstract available


  86. DESHPANDE D, Alffenaar JC, Koser CU, Dheda K, et al
    d-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal.
    Clin Infect Dis. 2018;67.
    PubMed     Abstract available


  87. DESHPANDE D, Pasipanodya JG, Srivastava S, Bendet P, et al
    Gatifloxacin Pharmacokinetics/Pharmacodynamics-based Optimal Dosing for Pulmonary and Meningeal Multidrug-resistant Tuberculosis.
    Clin Infect Dis. 2018;67.
    PubMed     Abstract available


  88. PASIPANODYA JG, Smythe W, Merle CS, Olliaro PL, et al
    Artificial intelligence-derived 3-Way Concentration-dependent Antagonism of Gatifloxacin, Pyrazinamide, and Rifampicin During Treatment of Pulmonary Tuberculosis.
    Clin Infect Dis. 2018;67.
    PubMed     Abstract available


  89. DESHPANDE D, Pasipanodya JG, Mpagama SG, Srivastava S, et al
    Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis.
    Clin Infect Dis. 2018;67.
    PubMed     Abstract available


  90. DESHPANDE D, Srivastava S, Nuermberger E, Koeuth T, et al
    Multiparameter Responses to Tedizolid Monotherapy and Moxifloxacin Combination Therapy Models of Children With Intracellular Tuberculosis.
    Clin Infect Dis. 2018;67.
    PubMed     Abstract available


  91. GUMBO T, Alffenaar JC
    Pharmacokinetic/Pharmacodynamic Background and Methods and Scientific Evidence Base for Dosing of Second-line Tuberculosis Drugs.
    Clin Infect Dis. 2018;67.
    PubMed     Abstract available


  92. GANMAA D, Khudyakov P, Buyanjargal U, Jargalsaikhan B, et al
    Prevalence and determinants of QuantiFERON-diagnosed tuberculosis infection in 9,810 Mongolian schoolchildren.
    Clin Infect Dis. 2018 Nov 27. pii: 5210883. doi: 10.1093.
    PubMed     Abstract available


  93. CUBILLOS-ANGULO JM, Arriaga MB, Silva EC, Muller BLA, et al
    Polymorphisms in TLR4 and TNFA and Risk of Mycobacterium tuberculosis Infection and Development of Active Disease in Contacts of Tuberculosis Cases in Brazil: A Prospective Cohort Study.
    Clin Infect Dis. 2018 Nov 24. pii: 5204461. doi: 10.1093/cid/ciy1001.
    PubMed     Abstract available


  94. DORJEE K, Topgyal S, Dorjee C, Tsundue T, et al
    High Prevalence of Active and Latent Tuberculosis in Children and Adolescents in Tibetan Schools in India: The Zero TB Kids Initiative in Tibetan Refugee Children.
    Clin Infect Dis. 2018 Nov 20. pii: 5193441. doi: 10.1093.
    PubMed     Abstract available


  95. RAJAN JV, Semitala FC, Mehta T, Seielstad M, et al
    A Novel, 5-Transcript, Whole-blood Gene-expression Signature for Tuberculosis Screening Among People Living With Human Immunodeficiency Virus.
    Clin Infect Dis. 2018 Nov 20. pii: 5193271. doi: 10.1093.
    PubMed     Abstract available


  96. MIGLIORI GB
    Evolution of programmatic definitions used in tuberculosis prevention and care.
    Clin Infect Dis. 2018 Nov 20. pii: 5193464. doi: 10.1093.
    PubMed    


  97. TING DSW, Tan TE, Lim CCT
    Development and Validation of a Deep Learning System for Detection of Active Pulmonary Tuberculosis on Chest Radiographs: Clinical and Technical Considerations.
    Clin Infect Dis. 2018 Nov 12. pii: 5173988. doi: 10.1093.
    PubMed    


  98. HWANG EJ, Park S, Jin KN, Kim JI, et al
    Development and Validation of a Deep Learning-Based Automatic Detection Algorithm for Active Pulmonary Tuberculosis on Chest Radiographs.
    Clin Infect Dis. 2018 Nov 12. pii: 5174137. doi: 10.1093.
    PubMed     Abstract available


  99. LOWENTHAL P, Lin SG, Desmond E, Shah N, et al
    Evaluation of the impact of a sequencing assay for detection of drug resistance on the clinical management of tuberculosis.
    Clin Infect Dis. 2018 Nov 1. pii: 5154873. doi: 10.1093.
    PubMed     Abstract available


  100. TRAUER JM, Dodd PJ, Gomes MGM, Gomez GB, et al
    The Importance of Heterogeneity to the Epidemiology of Tuberculosis.
    Clin Infect Dis. 2018 Nov 1. pii: 5154892. doi: 10.1093.
    PubMed     Abstract available


    October 2018
  101. HUANG H, Ding N, Yang T, Li C, et al
    Cross-sectional whole-genome sequencing and epidemiological study of multidrug-resistant Mycobacterium tuberculosis in China.
    Clin Infect Dis. 2018 Oct 15. pii: 5130581. doi: 10.1093.
    PubMed     Abstract available


    September 2018
  102. LESOSKY M, Rangaka MX, Pienaar C, Coussens AK, et al
    Plasma biomarkers to detect prevalent, or predict progressive, HIV-1-associated tuberculosis.
    Clin Infect Dis. 2018 Sep 26. pii: 5106993. doi: 10.1093.
    PubMed     Abstract available


  103. VAN KAMPEN SC, Jones R, Kisembo H, Houben RMGJ, et al
    Chronic respiratory symptoms and lung abnormalities among people with a history of tuberculosis in Uganda: a national survey.
    Clin Infect Dis. 2018 Sep 18. pii: 5099459. doi: 10.1093.
    PubMed     Abstract available


  104. FOX GJ, Nguyen VN, Dinh NS, Nghiem LPH, et al
    Post-treatment Mortality Among Patients With Tuberculosis: A Prospective Cohort Study of 10 964 Patients in Vietnam.
    Clin Infect Dis. 2018 Sep 7. pii: 5092716. doi: 10.1093.
    PubMed     Abstract available


  105. BUI DP, Oren E, Roe DJ, Brown HE, et al
    A Case Control Study to Identify Community Venues Associated with Genetically Clustered Multidrug-Resistant Tuberculosis Disease in Lima, Peru.
    Clin Infect Dis. 2018 Sep 5. pii: 5090843. doi: 10.1093.
    PubMed     Abstract available


    August 2018
  106. STEIN CM, Nsereko M, Malone LL, Okware B, et al
    Long-term stability of resistance to latent M. tuberculosis infection in highly exposed TB household contacts in Kampala, Uganda.
    Clin Infect Dis. 2018 Aug 28. pii: 5085255. doi: 10.1093.
    PubMed     Abstract available


  107. ZHAO Y, Fox T, Manning K, Stewart A, et al
    Improved treatment outcomes with bedaquiline when substituted for second-line injectable agents in multidrug resistant tuberculosis: a retrospective cohort study.
    Clin Infect Dis. 2018 Aug 24. pii: 5079132. doi: 10.1093.
    PubMed     Abstract available


    July 2018
  108. NGWIRA LG, Corbett EL, Khundi M, Barnes GL, et al
    Screening for tuberculosis with Xpert MTB/RIF versus fluorescent microscopy among adults newly diagnosed with HIV in rural Malawi: a cluster randomized trial (CHEPETSA).
    Clin Infect Dis. 2018 Jul 27. pii: 5060257. doi: 10.1093.
    PubMed     Abstract available


  109. HOUBEN RMGJ, Lalli M, Kranzer K, Menzies NA, et al
    What if they don't have tuberculosis? The consequences and trade-offs involved in false-positive diagnoses of tuberculosis.
    Clin Infect Dis. 2018 Jul 5. pii: 5049169. doi: 10.1093.
    PubMed     Abstract available


    June 2018
  110. SVENSSON EM, Svensson RJ, Te Brake LHM, Boeree MJ, et al
    The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis.
    Clin Infect Dis. 2018;67:34-41.
    PubMed     Abstract available


  111. MOORE CC, Jacob ST, Banura P, Zhang J, et al
    Etiology of Sepsis in Uganda using a Quantitative PCR-based TaqMan Array Card.
    Clin Infect Dis. 2018 Jun 4. pii: 5032704. doi: 10.1093.
    PubMed     Abstract available


    May 2018
  112. DIAN S, Rahmadi R, Laarhoven AV, Ganiem AR, et al
    Predicting mortality of tuberculous meningitis.
    Clin Infect Dis. 2018 May 31. pii: 5025876. doi: 10.1093.
    PubMed    


  113. GARCIA-PRATS AJ, Draper HR, Finlayson H, Winckler J, et al
    Clinical and cardiac safety of long-term levofloxacin in children treated for multidrug-resistant tuberculosis.
    Clin Infect Dis. 2018 May 16. pii: 4996923. doi: 10.1093.
    PubMed     Abstract available


    April 2018
  114. XIE YL, Cronin WA, Proschan M, Oatis R, et al
    Transmission of Mycobacterium tuberculosis from patients who are nucleic acid amplification test- negative.
    Clin Infect Dis. 2018 Apr 24. pii: 4984625. doi: 10.1093.
    PubMed     Abstract available


  115. ZUUR MA, Pasipanodya JG, van Soolingen D, van der Werf TS, et al
    Intermediate Susceptibility Dose-Dependent Breakpoints For High Dose Rifampicin, Isoniazid and Pyrazinamide Treatment in multidrug-resistant tuberculosis Programmes.
    Clin Infect Dis. 2018 Apr 24. pii: 4984540. doi: 10.1093.
    PubMed     Abstract available


  116. VON REYN CF, Horsburgh CR
    Non-tuberculous mycobacteria and testing for LTBI.
    Clin Infect Dis. 2018 Apr 18. pii: 4975392. doi: 10.1093.
    PubMed    


    March 2018
  117. JOHNSON KT, Churchyard GJ, Sohn H, Dowdy DW, et al
    Cost-effectiveness of preventive therapy for tuberculosis with isoniazid and rifapentine versus isoniazid alone in high-burden settings.
    Clin Infect Dis. 2018 Mar 30. pii: 4956926. doi: 10.1093.
    PubMed     Abstract available


  118. VAN LAARHOVEN A, Koeken VACM, Dian S, Ganiem AR, et al
    Neuromarker Levels Also Predict Mortality in Adult Tuberculous Meningitis.
    Clin Infect Dis. 2018 Mar 30. pii: 4956701. doi: 10.1093.
    PubMed    


  119. FRIGATI L, Archary M, Rabie H, Penazzato M, et al
    Priorities for Decreasing Morbidity and Mortality in Children With Advanced HIV Disease.
    Clin Infect Dis. 2018;66.
    PubMed     Abstract available


  120. FORD N, Meintjes G, Calmy A, Bygrave H, et al
    Managing Advanced HIV Disease in a Public Health Approach.
    Clin Infect Dis. 2018;66.
    PubMed     Abstract available


  121. PASIPANODYA JG, Gumbo T
    Individualizing Tuberculosis Treatment: Are Tuberculosis Programs In High Burden Settings Ready For Prime Time Therapeutic Drug Monitoring?
    Clin Infect Dis. 2018 Mar 3. pii: 4919551. doi: 10.1093.
    PubMed    


  122. SEKAGGYA-WILTSHIRE C, von Braun A, Lamorde M, Ledergerber B, et al
    Delayed Sputum Conversion in TB-HIV Co-Infected Patients with Low Isoniazid and Rifampicin Concentrations.
    Clin Infect Dis. 2018 Mar 3. pii: 4919550. doi: 10.1093.
    PubMed     Abstract available


    February 2018
  123. BROOKS KM, George JM, Pau AK, Rupert A, et al
    Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug-Drug Interaction Study of Dolutegravir with Once-Weekly Isoniazid and Rifapentine.
    Clin Infect Dis. 2018 Feb 3. pii: 4836314. doi: 10.1093.
    PubMed     Abstract available


    January 2018
  124. YU MC, Chiang CY, Lee JJ, Chien ST, et al
    Treatment outcomes of multidrug-resistant tuberculosis in Taiwan: tackling loss to follow-up.
    Clin Infect Dis. 2018 Jan 31. pii: 4831095. doi: 10.1093.
    PubMed     Abstract available


  125. MARAIS S, Roos I, Mitha A, Mabusha SJ, et al
    Spinal tuberculosis: Clinicoradiological findings in 274 patients.
    Clin Infect Dis. 2018 Jan 11. pii: 4797620. doi: 10.1093.
    PubMed     Abstract available


  126. DEGNER NR, Wang JY, Golub JE, Karakousis PC, et al
    Metformin Use Reverses the Increased Mortality Associated With Diabetes Mellitus During Tuberculosis Treatment.
    Clin Infect Dis. 2018;66:198-205.
    PubMed     Abstract available


  127. LACOURSE SM, Cranmer LM, Njuguna IN, Gatimu J, et al
    Urine TB lipoarabinomannan (LAM) predicts mortality in hospitalized HIV-infected children.
    Clin Infect Dis. 2018 Jan 6. pii: 4792803. doi: 10.1093.
    PubMed     Abstract available


    December 2017
  128. BRUST JCM, Shah NS, Mlisana K, Moodley P, et al
    Improved survival and cure rates with concurrent treatment for MDR-TB/HIV co-infection in South Africa.
    Clin Infect Dis. 2017 Dec 26. pii: 4774985. doi: 10.1093/cid/cix1125.
    PubMed     Abstract available


    November 2017
  129. KOSER CU, Koeser LA, Dolinger DL
    Limited evidence for need for region-specific, genotypic drug-susceptibility assays for Mycobacterium tuberculosis.
    Clin Infect Dis. 2017 Nov 22. pii: 4647356. doi: 10.1093/cid/cix1042.
    PubMed    


  130. GRIESEL R, Stewart A, van der Plas H, Sikhondze W, et al
    Optimizing Tuberculosis Diagnosis in HIV-Infected Inpatients Meeting the Criteria of Seriously Ill in the WHO Algorithm.
    Clin Infect Dis. 2017 Nov 6. doi: 10.1093.
    PubMed     Abstract available


    October 2017
  131. HUAMAN MA, Ticona E, Miranda G, Kryscio RJ, et al
    The Relationship between Latent Tuberculosis Infection and Acute Myocardial Infarction.
    Clin Infect Dis. 2017 Oct 21. doi: 10.1093.
    PubMed     Abstract available


  132. GUTHRIE JL, Kong C, Roth D, Jorgensen D, et al
    Molecular Epidemiology of Tuberculosis in British Columbia, Canada - A 10-Year Retrospective Study.
    Clin Infect Dis. 2017 Oct 21. doi: 10.1093.
    PubMed     Abstract available


  133. MARTINEZ L, Zhu L, Castellanos ME, Liu Q, et al
    Glycemic Control and the Prevalence of Tuberculosis Infection: A Population-based Observational Study.
    Clin Infect Dis. 2017 Oct 20. doi: 10.1093.
    PubMed     Abstract available


  134. OSMAN M, Lee K, Du Preez K, Dunbar R, et al
    Excellent Treatment Outcomes in Children Treated for Tuberculosis Under Routine Operational Conditions in Cape Town, South Africa.
    Clin Infect Dis. 2017;65:1444-1452.
    PubMed     Abstract available


  135. VANINO E, Tadolini M, Attard L, Po C, et al
    Systematic Tuberculosis Screening in Asylum Seekers in Italy.
    Clin Infect Dis. 2017;65:1407-1409.
    PubMed     Abstract available


  136. DOBLER CC
    Cumulative Incidence and Incidence Rate Ratio for Estimation of Risk of Tuberculosis in Patients With Cancer.
    Clin Infect Dis. 2017;65:1423.
    PubMed    


  137. FARHAT MR, Jacobson KR, Franke MF, Kaur D, et al
    Fluoroquinolone Resistance Mutation Detection Is Equivalent to Culture-Based Drug Sensitivity Testing for Predicting Multidrug-Resistant Tuberculosis Treatment Outcome: A Retrospective Cohort Study.
    Clin Infect Dis. 2017;65:1364-1370.
    PubMed     Abstract available


  138. MCKENNA L, Frick M, Lee C, Namutamba D, et al
    A Community Perspective on the Inclusion of Pregnant Women in Tuberculosis Drug Trials.
    Clin Infect Dis. 2017;65:1383-1387.
    PubMed     Abstract available


  139. ADU-GYAMFI CG, Snyman T, Hoffmann CJ, Martinson NA, et al
    Plasma Indoleamine 2, 3-Dioxygenase, a Biomarker for Tuberculosis in Human Immunodeficiency Virus-Infected Patients.
    Clin Infect Dis. 2017;65:1356-1358.
    PubMed     Abstract available


  140. COOKSON ST, Maloney SA
    Keeping Up With a World in Motion: Screening Strategies for Migrating Populations.
    Clin Infect Dis. 2017;65:1410-1411.
    PubMed    


  141. LEE RS, Howden BP
    The Critical Importance of Sampling Fraction to Inferences of Mycobacterium tuberculosis Transmission.
    Clin Infect Dis. 2017 Oct 13. doi: 10.1093.
    PubMed    


    September 2017
  142. LIN HH, Wu CY, Wang CH, Fu H, et al
    Association of obesity, diabetes, and risk of tuberculosis: two population-based cohorts.
    Clin Infect Dis. 2017 Sep 26. doi: 10.1093.
    PubMed     Abstract available


  143. SALAZAR-AUSTIN N, Hoffmann J, Cohn S, Mashabela F, et al
    Poor Obstetric and Infant Outcomes in HIV-Infected Pregnant Women with Tuberculosis in South Africa: The Tshepiso Study.
    Clin Infect Dis. 2017 Sep 26. doi: 10.1093.
    PubMed     Abstract available


  144. THAO LTP, Heemskerk AD, Geskus RB, Mai NTH, et al
    Prognostic models for 9 month mortality in tuberculous meningitis.
    Clin Infect Dis. 2017 Sep 26. doi: 10.1093.
    PubMed     Abstract available


  145. NEMES E, Hesseling AC, Tameris M, Mauff K, et al
    Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin (BCG) for Infants of HIV Infected Mothers: A Phase 2 Randomized Controlled Trial.
    Clin Infect Dis. 2017 Sep 26. doi: 10.1093.
    PubMed     Abstract available


  146. SIVRO A, McKinnon LR, Yende-Zuma N, Gengiah S, et al
    Plasma Cytokine Predictors of Tuberculosis Recurrence in Antiretroviral-Treated Human Immunodeficiency Virus-infected Individuals from Durban, South Africa.
    Clin Infect Dis. 2017;65:819-826.
    PubMed     Abstract available


    August 2017
  147. BACCANI I, Antonelli A, Galano A, Bartalesi F, et al
    Linezolid-resistant Enterococcus faecalis infection following prolonged low-dosage linezolid treatment for multi-drug-resistant tuberculosis.
    Clin Infect Dis. 2017 Aug 20. doi: 10.1093.
    PubMed    


  148. DRANCOURT M
    Please, no more gastric aspirate to diagnose pulmonary tuberculosis in children.
    Clin Infect Dis. 2017 Aug 19. doi: 10.1093.
    PubMed    


  149. MUNOZ L, Santin M, Alcaide F, Ruiz-Serrano MJ, et al
    QuantiFERON(R)-TB Gold In-Tube as a confirmatory test for tuberculin skin test in tuberculosis contact tracing: A non-inferiority clinical trial.
    Clin Infect Dis. 2017 Aug 18. doi: 10.1093.
    PubMed     Abstract available


  150. ARGUELLO PEREZ E, Seo SK, Schneider WJ, Eisenstein C, et al
    Management of Latent Tuberculosis Infection among Healthcare Workers: 10-year Experience at a Single Center.
    Clin Infect Dis. 2017 Aug 17. doi: 10.1093.
    PubMed     Abstract available


  151. SCHECHTER MC, Bizune D, Kagei M, Machaidze M, et al
    Time to Sputum Culture Conversion and Treatment Outcomes Among Patients with Isoniazid-Resistant Tuberculosis in Atlanta, Georgia.
    Clin Infect Dis. 2017 Aug 3. doi: 10.1093.
    PubMed     Abstract available


    July 2017
  152. SALINAS JL, Armstrong LR, Silk BJ, Haddad MB, et al
    Factors Associated with All-Cause Mortality among Patients with Multidrug-Resistant Tuberculosis - United States, 1993-2013.
    Clin Infect Dis. 2017 Jul 29. doi: 10.1093.
    PubMed     Abstract available


  153. FLORIDIA M, Ciccacci F, Andreotti M, Hassane A, et al
    Tuberculosis case finding with combined rapid point of care assays (Xpert(R) MTB/RIF and LAM) in HIV-positive individuals starting antiretroviral treatment in Mozambique.
    Clin Infect Dis. 2017 Jul 23. doi: 10.1093.
    PubMed     Abstract available


    June 2017
  154. SMITH SE, Pratt R, Trieu L, Barry PM, et al
    Epidemiology of pediatric multidrug-resistant tuberculosis in the United States, 1993-2014.
    Clin Infect Dis. 2017 Jun 19. doi: 10.1093.
    PubMed     Abstract available


  155. MOORE DP, Higdon MM, Hammitt LL, Prosperi C, et al
    The Incremental Value of Repeated Induced Sputum and Gastric Aspirate Samples for the Diagnosis of Pulmonary Tuberculosis in Young Children With Acute Community-Acquired Pneumonia.
    Clin Infect Dis. 2017;64.
    PubMed     Abstract available


  156. ROHLWINK UK, Mauff K, Wilkinson KA, Enslin N, et al
    Biomarkers of cerebral injury and inflammation in pediatric tuberculous meningitis.
    Clin Infect Dis. 2017 Jun 9. doi: 10.1093.
    PubMed     Abstract available


    May 2017
  157. SANDUL AL, Nwana N, Holcombe JM, Lobato MN, et al
    High Rate of Treatment Completion in Program Settings with 12-Dose Weekly Isoniazid and Rifapentine (3HP) for Latent Mycobacterium tuberculosis Infection.
    Clin Infect Dis. 2017 May 30. doi: 10.1093.
    PubMed     Abstract available


  158. FURIN J, Cox H
    To Test or Not to Test? Ending the Age-Old Debate for Drug-Resistant Tuberculosis.
    Clin Infect Dis. 2017 May 26. doi: 10.1093.
    PubMed    


  159. AIBANA O, Franke MF, Huang CC, Galea JT, et al
    Impact of Vitamin A and Carotenoids on the Risk of Tuberculosis Progression.
    Clin Infect Dis. 2017 May 20. doi: 10.1093.
    PubMed     Abstract available


  160. KAWKITINARONG K, Suwanpimolkul G, Kateruttanakul P, Manosuthi W, et al
    Real-Life Clinical Practice of Using the Xpert MTB/RIF Assay in Thailand.
    Clin Infect Dis. 2017;64.
    PubMed     Abstract available


  161. MANSON AL, Abeel T, Galagan JE, Sundaramurthi JC, et al
    Mycobacterium tuberculosis Whole Genome Sequences From Southern India Suggest Novel Resistance Mechanisms and the Need for Region-Specific Diagnostics.
    Clin Infect Dis. 2017 May 12. doi: 10.1093.
    PubMed     Abstract available


  162. HARAUSZ EP, Leigh J, Garcia-Prats AJ, Furin J, et al
    Stability of Second-Line Tuberculosis Medications Mixed with Milk or Yogurt.
    Clin Infect Dis. 2017 May 6. doi: 10.1093.
    PubMed    


  163. SEIFERT M, Georghiou SB, Garfein RS, Catanzaro D, et al
    Impact of fluoroquinolone use on mortality among a cohort of suspected drug-resistant tuberculosis patients.
    Clin Infect Dis. 2017 May 5. doi: 10.1093.
    PubMed     Abstract available


  164. WALKER NF, Wilkinson KA, Meintjes G, Tezera LB, et al
    Matrix Degradation in Human Immunodeficiency Virus Type 1-Associated Tuberculosis and Tuberculosis Immune Reconstitution Inflammatory Syndrome: A Prospective Observational Study.
    Clin Infect Dis. 2017 May 5. doi: 10.1093.
    PubMed     Abstract available


  165. HEEMSKERK AD, Nguyen MTH, Dang HTM, Vinh Nguyen CV, et al
    Clinical Outcomes of Patients With Drug-Resistant Tuberculous Meningitis Treated With an Intensified Antituberculosis Regimen.
    Clin Infect Dis. 2017 May 4. doi: 10.1093.
    PubMed     Abstract available


    April 2017
  166. AUNG HL, Nyunt WW, Fong Y, Cook GM, et al
    First two extensively drug-resistant tuberculosis cases from Myanmar treated with bedaquiline.
    Clin Infect Dis. 2017 Apr 24. doi: 10.1093.
    PubMed    


  167. PHILLIPS PP
    Setting tuberculosis regimen development on a firm foundation.
    Clin Infect Dis. 2017 Apr 10. doi: 10.1093.
    PubMed    


  168. BONNETT LJ, Ken-Dror G, Koh G, Davies GR, et al
    Comparing the efficacy of drug regimens for pulmonary tuberculosis: meta-analysis of endpoints in early phase clinical trials.
    Clin Infect Dis. 2017 Apr 10. doi: 10.1093.
    PubMed     Abstract available


  169. RAOULT D
    Old Antibiotics for Tuberculosis.
    Clin Infect Dis. 2017;64:983.
    PubMed    


  170. BROGER T, Basu Roy R, Filomena A, Greef CH, et al
    Diagnostic Performance of Tuberculosis-Specific IgG Antibody Profiles in Patients with Presumptive Tuberculosis from Two Continents.
    Clin Infect Dis. 2017;64:947-955.
    PubMed     Abstract available


    March 2017
  171. JANSSEN S, Schutz C, Ward A, Nemes E, et al
    Mortality in Severe HIV-TB Associates with Innate Immune Activation and Dysfunction of Monocytes.
    Clin Infect Dis. 2017 Mar 24. doi: 10.1093.
    PubMed     Abstract available


  172. MARKS SM, Mase SR, Bamrah Morris S
    Systematic Review, Meta-Analysis, and Cost Effectiveness of Treatment of Latent Tuberculosis Infection to Reduce Progression to Multidrug-Resistant Tuberculosis.
    Clin Infect Dis. 2017 Mar 14. doi: 10.1093.
    PubMed     Abstract available


  173. COLLIER D, Iwuji C, Derache A, de Oliveira T, et al
    Virological Outcomes of Second-line Protease Inhibitor-Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis.
    Clin Infect Dis. 2017 Mar 13. doi: 10.1093.
    PubMed     Abstract available


    February 2017
  174. ROCKWOOD N N, Pasipanodya JG, Denti P, Sirgel F, et al
    Concentration-dependent antagonism and culture conversion in pulmonary tuberculosis.
    Clin Infect Dis. 2017 Feb 16. doi: 10.1093.
    PubMed    


  175. RAVIMOHAN S, Tamuhla N, Nfanyana K, Ni H, et al
    Elevated pre-ART CD39+CD8+ T-cell frequency is associated with early mortality in advanced HIV/TB.
    Clin Infect Dis. 2017 Feb 16. doi: 10.1093.
    PubMed    


  176. COWAN JF, Chandler AS, Kracen E, Park DR, et al
    Clinical Impact and Cost-effectiveness of Xpert MTB/RIF Testing in Hospitalized Patients With Presumptive Pulmonary Tuberculosis in the United States.
    Clin Infect Dis. 2017;64:482-489.
    PubMed    


  177. MARAIS BJ, Heemskerk AD, Marais SS, van Crevel R, et al
    Standardized Methods for Enhanced Quality and Comparability of Tuberculous Meningitis Studies.
    Clin Infect Dis. 2017;64:501-509.
    PubMed    


  178. JOHNSTON JC, Campbell JR, Menzies D
    Effect of intermittency on treatment outcomes in pulmonary tuberculosis: an updated systematic review and meta-analysis.
    Clin Infect Dis. 2017 Feb 14. doi: 10.1093.
    PubMed    


  179. JACOBSON KR, Barnard M, Kleinman MB, Streicher EM, et al
    Implications of failure to routinely diagnose resistance to second-line drugs in patients with rifampicin-resistant tuberculosis on Xpert MTB/RIF: a multisite observational study.
    Clin Infect Dis. 2017 Feb 12. doi: 10.1093.
    PubMed    


    January 2017
  180. PROANO A, Bravard MA, Lopez JW, Lee GO, et al
    Dynamics of Cough Frequency in Adults Undergoing Treatment for Pulmonary Tuberculosis.
    Clin Infect Dis. 2017 Jan 25. doi: 10.1093.
    PubMed     Abstract available


  181. LEWINSOHN DM, Leonard MK, LoBue PA, Cohn DL, et al
    Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children.
    Clin Infect Dis. 2017;64:111-115.
    PubMed     Abstract available


    December 2016
  182. LEE MR, Huang YP, Kuo YT, Luo CH, et al
    Diabetes mellitus and latent tuberculosis infection: a systemic review and meta-analysis.
    Clin Infect Dis. 2016.
    PubMed     Abstract available


  183. CHENG MP, Abou Chakra CN, Yansouni CP, Cnossen S, et al
    Risk of Active Tuberculosis in Patients with Cancer: A Systematic Review and Meta-Analysis.
    Clin Infect Dis. 2016.
    PubMed     Abstract available


  184. CHENG MP, Chakra CN, Yansouni CP, Cnossen S, et al
    Risk of Active Tuberculosis in Patients With Cancer: A Systematic Review and Metaanalysis.
    Clin Infect Dis. 2016 Dec 13. doi: 10.1093.
    PubMed    


  185. COWAN JF, Chandler AS, Kracen E, Park DR, et al
    Clinical Impact and Cost-Effectiveness of Xpert MTB/RIF Testing in Hospitalized Patients with Presumptive Pulmonary Tuberculosis in the United States.
    Clin Infect Dis. 2016.
    PubMed     Abstract available


  186. LEWINSOHN DM, Leonard MK, LoBue PA, Cohn DL, et al
    Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children.
    Clin Infect Dis. 2016.
    PubMed     Abstract available


  187. VINNARD C, King L, Munsiff S, Crossa A, et al
    The Long-Term Mortality of Tuberculosis Meningitis Patients in New York City: A Cohort Study.
    Clin Infect Dis. 2016.
    PubMed     Abstract available


    November 2016
  188. GUMBO T, Makhene MK, Seddon JA
    Partnerships to Design Novel Regimens to Treat Childhood Tuberculosis, Sui Generis: The Road Ahead.
    Clin Infect Dis. 2016;63.
    PubMed     Abstract available


  189. SRIVASTAVA S, Deshpande D, Pasipanodya J, Nuermberger E, et al
    Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks.
    Clin Infect Dis. 2016;63.
    PubMed     Abstract available


  190. DESHPANDE D, Srivastava S, Nuermberger E, Pasipanodya JG, et al
    A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way.
    Clin Infect Dis. 2016;63.
    PubMed     Abstract available


  191. DESHPANDE D, Srivastava S, Nuermberger E, Pasipanodya JG, et al
    Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo.
    Clin Infect Dis. 2016;63.
    PubMed     Abstract available


  192. DESHPANDE D, Srivastava S, Pasipanodya JG, Bush SJ, et al
    Linezolid for Infants and Toddlers With Disseminated Tuberculosis: First Steps.
    Clin Infect Dis. 2016;63.
    PubMed     Abstract available


  193. SRIVASTAVA S, Deshpande D, Pasipanodya JG, Thomas T, et al
    A Combination Regimen Design Program Based on Pharmacodynamic Target Setting for Childhood Tuberculosis: Design Rules for the Playground.
    Clin Infect Dis. 2016;63.
    PubMed     Abstract available


  194. SWAMINATHAN S, Pasipanodya JG, Ramachandran G, Hemanth Kumar AK, et al
    Drug Concentration Thresholds Predictive of Therapy Failure and Death in Children With Tuberculosis: Bread Crumb Trails in Random Forests.
    Clin Infect Dis. 2016;63.
    PubMed     Abstract available


  195. SEDDON JA, Makhene MK
    Harnessing Novel Quantitative Pharmacology Approaches to Optimize the Treatment of Children With Tuberculosis.
    Clin Infect Dis. 2016;63.
    PubMed    


    October 2016
  196. ALFFENAAR JC, Tiberi S, Verbeeck RK, Heysell SK, et al
    Therapeutic Drug Monitoring in Tuberculosis: Practical Application for Physicians.
    Clin Infect Dis. 2016.
    PubMed    


  197. NAHID P, Dorman SE, Alipanah N, Barry PM, et al
    Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.
    Clin Infect Dis. 2016;63:853-67.
    PubMed     Abstract available


    September 2016
  198. YANG JY, Han M, Koh Y, Kim WS, et al
    Effects of Corticosteroids on Critically Ill Pulmonary Tuberculosis Patients with Acute Respiratory Failure: A Propensity Analysis of Mortality.
    Clin Infect Dis. 2016.
    PubMed     Abstract available


    March 2016
  199. BAHR NC, Marais S, Caws M, van Crevel R, et al
    GeneXpert MTB/Rif to Diagnose Tuberculous Meningitis: Perhaps the First Test but not the Last.
    Clin Infect Dis. 2016.
    PubMed     Abstract available


    January 2016
  200. HSU DC, Faldetta KF, Pei L, Sheikh V, et al
    A Paradoxical Treatment for a Paradoxical Condition: Infliximab Use in Three Cases of Mycobacterial IRIS.
    Clin Infect Dis. 2016;62:258-61.
    PubMed     Abstract available


    December 2015
  201. GUPTA A, Mathad JS, Abdel-Rahman SM, Albano JD, et al
    Towards Earlier Inclusion of Pregnant and Postpartum Women in TB Drug Trials: Consensus Statements from an International Expert Panel.
    Clin Infect Dis. 2015.
    PubMed     Abstract available


    November 2015
  202. RAVIMOHAN S, Tamuhla N, Nfanyana K, Steenhoff AP, et al
    Robust reconstitution of TB-specific polyfunctional CD4+ T-cell responses and rising systemic IL-6 in paradoxical TB-IRIS.
    Clin Infect Dis. 2015.
    PubMed     Abstract available


  203. AKKERMAN OW, Odish OF, Bolhuis MS, de Lange WC, et al
    Pharmacokinetics of bedaquiline in cerebrospinal fluid and serum in multidrug-resistant tuberculous meningitis.
    Clin Infect Dis. 2015.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Tuberculosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: